Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Breast 3Sarcoma 2Gynecologic 2Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Solid Tumors 1Solid Tumor 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × pamiparib × Other solid neoplasm × Clear all
NCT02361723 2024-12-27

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

BeiGene

Phase 1 Completed
101 enrolled
Other solid neoplasm

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

NCT03994211 2024-10-26

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

BeiGene

Phase 1 Completed
25 enrolled 33 charts
Other solid neoplasm

Solid Tumor

NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
229 enrolled 46 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡